Research map: Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19–9 undergoing pancreatic ductal adenocarcinoma resection

Back to the article

Papers in this map

  1. ggplot2 · Hadley Wickham · 2016 · 34424 citations · Cited by this paper
  2. The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma · 2026 · Related
  3. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials · K. F Schulz · 2010 · 8928 citations · Cited by this paper
  4. Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials · 2026 · Related
  5. Reproducible Summary Tables with the gtsummary Package · Daniel,D. Sjoberg · 2021 · 1351 citations · Cited by this paper
  6. Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection · 2026 · Related
  7. Extracting, Computing and Exploring the Parameters of Statistical Models using R · Daniel Lüdecke · 2020 · 552 citations · Cited by this paper
  8. The evolving survival landscape in advanced non-small cell lung cancer: an interrupted time series analysis · 2026 · Related
  9. Time Series Analysis · W. N. Venables · 2002 · 472 citations · Cited by this paper
  10. Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing · 2026 · Related
  11. CA 19-9: Biochemical and Clinical Aspects · Salvatore Scarà · 2015 · 357 citations · Cited by this paper
  12. Quantitative and qualitative fecal immunochemical tests for colorectal cancer screening in Kazakhstan: a comparative study · 2026 · Related
  13. Carbohydrate antigen 19-9 — tumor marker: Past, present, and future · Tsinrong Lee · 2020 · 289 citations · Cited by this paper
  14. Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy · 2026 · Related
  15. Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases · Sun‐Young Kim · 2020 · 189 citations · Cited by this paper
  16. Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B? · 2026 · Related
  17. CA19-9 for detecting recurrence of pancreatic cancer · Azadeh Azizian · 2020 · 185 citations · Cited by this paper
  18. Cancer genome profiling in sarcomas: current status and future perspectives in Japan · 2026 · Related
  19. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy · Eran van Veldhuisen · 2018 · 95 citations · Cited by this paper
  20. Emerging trends in early-onset gastrointestinal cancers - a comparative review with late-onset cancers · 2026 · Related
  21. Neoadjuvant therapy for pancreatic cancer · Jean Gugenheim · 2021 · 95 citations · Cited by this paper
  22. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma · Shuichi Fujioka · 2007 · 66 citations · Cited by this paper
  23. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis · Chen Ye · 2020 · 53 citations · Cited by this paper
  24. Surgical Treatment of Pancreatic Ductal Adenocarcinoma · Kongyuan Wei · 2021 · 48 citations · Cited by this paper
  25. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a systematic review and meta-analysis · Boqiang Zhao · 2022 · 45 citations · Cited by this paper
  26. Reassessment of the clinical significance of portal–superior mesenteric vein invasion in borderline resectable pancreatic cancer · S. Hoshimoto · 2017 · 29 citations · Cited by this paper
  27. Preoperative CA 19‐9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma · Erin G. Brown · 2014 · 27 citations · Cited by this paper
  28. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype · Guopei Luo · 2016 · 26 citations · Cited by this paper
  29. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients · Guopei Luo · 2016 · 26 citations · Cited by this paper
  30. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis · Gian Carlo Mattiucci · 2018 · 24 citations · Cited by this paper
  31. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort · Marta Herreros‐Villanueva · 2020 · 23 citations · Cited by this paper
  32. Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer · Nana Kimura · 2020 · 19 citations · Cited by this paper
  33. Comparison of Urinary and Serum CA 19-9 as Markers of Early Stage Urothelial Carcinoma · Suparna Roy · 2013 · 18 citations · Cited by this paper
  34. Carbohydrate Antigen 19‐9 in Saliva · Gerhard Dyckhoff · 2011 · 14 citations · Cited by this paper
  35. Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute · Yajie Zhao · 2019 · 14 citations · Cited by this paper
  36. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer · Hao Liu · 2023 · 13 citations · Cited by this paper
  37. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy · Kojiro Omiya · 2025 · 8 citations · Cited by this paper
  38. Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database · Toshitaka Sugawara · 2024 · 6 citations · Cited by this paper
  39. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification · Aya Maekawa · 2025 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)